ADMA Biologics CEO Adam Grossman sells $1.76M in shares

Adam Grossman, CEO of ADMA Biologics, sold 147,000 shares of the company's stock, amounting to $1.76 million, on November 5, 2026. Prior to this, he exercised stock options to buy 105,000 shares for $567,000 on the same day under a pre-established Rule 10b5-1 trading plan. Since the shares were sold at $12.00 each, the stock has risen to $13.21, marking a 10% increase from the transaction price.

However, the shares have decreased about 28% year-to-date. According to InvestingPro, ADMA appears slightly undervalued, appearing on their Most Undervalued watchlist. The shares were sold in two separate transactions of 105,000 and 42,000 shares each at $12.00 per share. This sale coincides with ADMA's stock rebound, which saw a 16% gain over the previous week after initial struggles.

ADMA Biologics is valued at $2.93 billion, trading at a P/E ratio of 18.81 and holding a Financial Health Score of 3.62. Earlier on the same day, Grossman purchased 105,000 shares through stock option exercise for $567,000, with these shares becoming fully vested by February 26, 2028 upon meeting vesting criteria. As of the transactions, Grossman owns 2,070,777 shares of ADMA directly, including 282,529 unvested RSUs granted on February 9, 2026, 189,017 RSUs from a grant on February 19, 2025, 278,864 RSUs from a February 26, 2024 grant, and 143,424 RSUs from a grant on March 6, 2023.

He also indirectly owns 1,143,426 shares through Areth, LLC, and 580,957 shares through Hariden, LLC. ADMA Biologics recently reported Q3 2026 earnings, exceeding analysts' expectations with both earnings per share and revenue surpassing forecasts. The company posted $0.23 EPS, higher than the expected $0.20, and reported revenue of $141.1 million, surpassing the anticipated $138.12 million.

Revenue growth was notably driven by a 31% increase in ASCENIV sales, with higher utilization among existing patients and new prescribers. In response, Mizuho adjusted its price target for ADMA from $17.00 to $18.00, maintaining an Underperform rating.